The driving brain: the CNS in the pathogenesis and treatment of anorexia–cachexia syndrome

References

• Evans WJ, Morley JE, Argilés J et al. Cachexia: a new definition. Clin. Nutr.27(6), 793–799 (2008).
   PubMed Web of Science ®Google Scholar
• Schocken DD, Benjamin EJ, Fonarow GC et al. Prevention of heart failure: a scientific statement from the American Heart Association Councilson Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High BloodPressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation117(19), 2544–2565 (2008).
   PubMed Web of Science ®Google Scholar
• Kannel WB. Incidence and epidemiology of heart failure. Heart Fail. Rev.5(2), 167–173 (2000).
   PubMedGoogle Scholar
• Klein L, Gheorghiade M. Coronary artery disease and prevention of heart failure. Med. Clin. North Am.88(5), 1209–1235 (2004).
   PubMed Web of Science ®Google Scholar
• Dei Cas L, Metra M, Nodari S, Dei Cas A, Gheorghiade M. Prevention and management of chronic heart failure in patients at risk. Am. J. Cardiol.91(9A), 10F–17F (2003).
   Google Scholar
• Springer J, Filippatos G, Akashi YJ, Anker SD. Prognosis and therapy approaches of cardiac cachexia. Curr. Opin. Cardiol.21(3), 229–223 (2006).
   PubMed Web of Science ®Google Scholar
• Anker SD, Ponikowski P, Varney S et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet349(9058), 1050–1053 (1997).
   PubMed Web of Science ®Google Scholar
• Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA. Body mass index and mortality in heart failure: a meta-analysis. Am. Heart J.156(1), 13–22 (2008).
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB. Survival advantages of obesity in dialysis patients. Am. J. Clin. Nutr.81(3), 543–554 (2005).
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K. Recent advances in understanding the malnutrition–inflammation–cachexia syndrome in chronic kidney disease patients: what is next? Semin. Dial.18(5), 365–369 (2005).
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Block G, McAllister CJ, Humphreys MH, Kopple JD. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am. J. Clin. Nutr.80(2), 299–307 (2004).
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition–inflammation complex syndrome in dialysis patients: causes and consequences. Am. J. Kidney Dis.42(5), 864–881 (2003).
   PubMed Web of Science ®Google Scholar
• Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv. Chronic Kidney Dis.14(1), 82–99 (2007).
   PubMed Web of Science ®Google Scholar
• Gray-Donald K, Gibbons L, Shapiro SH, Macklem PT, Martin JG. Nutritional status and mortality in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.153(3), 961–966 (1996).
   PubMed Web of Science ®Google Scholar
• Nishimura K, Tsukino M. Clinical course and prognosis of patients with chronic obstructive pulmonary disease. Curr. Opin. Pulm. Med.6(2), 127–132 (2000).
   PubMedGoogle Scholar
• Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.157(6 Pt 1), 1791–1797 (1998).
   PubMed Web of Science ®Google Scholar
• Celli BR, Cote CG, Marin JM et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med.350(10), 1005–1012 (2004).
   PubMed Web of Science ®Google Scholar
• Marchesini G, Bianchi G, Merli M et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology124(7), 1792–1801 (2003).
   PubMed Web of Science ®Google Scholar
• Møller S, Bendtsen F, Christensen E, Henriksen JH. Prognostic variables in patients with cirrhosis and oesophageal varices without prior bleeding. J. Hepatol.21(6), 940–946 (1994).
   PubMed Web of Science ®Google Scholar
• Mendenhall C, Roselle GA, Gartside P, Moritz T. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration Cooperative Studies. Alcohol Clin. Exp. Res.19(3), 635–641 (1995).
   PubMed Web of Science ®Google Scholar
• Walsh D, Rybicki L. Symptom clustering in advanced cancer. Support Care Cancer14(8), 831–836 (2006).
   PubMed Web of Science ®Google Scholar
• Dewys WD, Begg C, Lavin PT et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med.69(4), 491–497 (1980).
   PubMed Web of Science ®Google Scholar
• Kotler DP. Cachexia. Ann. Intern. Med.133(8), 622–634 (2000).
   PubMed Web of Science ®Google Scholar
• Isenring EA, Capra S, Bauer JD. Nutrition intervention is beneficial in oncology outpatients receiving radiotherapy to the gastrointestinal or head and neck area. Br. J. Cancer91(3), 447–452 (2004).
   PubMed Web of Science ®Google Scholar
• Sutton LM, Demark-Wahnefried W, Clipp EC. Management of terminal cancer in elderly patients. Lancet Oncol.4(3), 149–157 (2003).
   Google Scholar
• Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia–cachexia syndrome. Cochrane Database Syst. Rev.18(2), CD004310 (2005).
   Google Scholar
• Jatoi A, Windschitl HE, Loprinzi CL et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J. Clin. Oncol.20(2), 567–573 (2002).
   PubMed Web of Science ®Google Scholar
• Ramos EJ, Suzuki S, Marks D, Inui A, Asakawa A, Meguid MM. Cancer anorexia–cachexia syndrome: cytokines and neuropeptides. Curr. Opin. Clin. Nutr. Metab. Care7(4), 427–434 (2004).
   PubMed Web of Science ®Google Scholar
• Dezube BJ, Sherman ML, Fridovich-Keil JL, Allen-Ryan J, Pardee AB. Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study. Cancer Immunol. Immunother.36(1), 57–60 (1993).
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Loprinzi CL, Mailliard JA et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J. Clin. Oncol.13(11), 2856–2859 (1995).
   PubMed Web of Science ®Google Scholar
• Wigmore SJ, Fearon KC, Maingay JP, Ross JA. Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin. Sci. (Lond.)92(2), 215–221 (1997).
   PubMed Web of Science ®Google Scholar
• Dewey A, Baughan C, Dean T, Higgins B, Johnson I. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst. Rev.1, CD004597 (2007).
   Google Scholar
• Storer TW, Woodhouse LJ, Sattler F et al. A randomized, placebo-controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment. J. Clin. Endocrinol. Metab.90(8), 4474–4482 (2005).
   PubMed Web of Science ®Google Scholar
• Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA281(14), 1275–1281 (1999).
   PubMed Web of Science ®Google Scholar
• Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic–androgenic steroids. Clin. Ther.23(9), 1355–1390 (2001).
   PubMed Web of Science ®Google Scholar
• Cominelli S, Raguso CA, Karsegard L et al. Weight-losing HIV-infected patients on recombinant human growth hormone for 12 wk: a national study. Nutrition18(7–8), 583–586 (2002).
   Google Scholar
• Hansen TB, Gram J, Jensen PB et al. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study. Clin. Nephrol.53(2), 99–107 (2000).
   Google Scholar
• Fazio S, Palmieri EA, Affuso F et al. Effects of growth hormone on exercise capacity and cardiopulmonary performance in patients with chronic heart failure. J. Clin. Endocrinol. Metab.92(11), 4218–4223 (2007).
   PubMedGoogle Scholar
• Shih A, Jackson KC 2nd. Role of corticosteroids in palliative care. J. Pain Palliat. Care Pharmacother.21(4), 69–76 (2007).
   PubMedGoogle Scholar
• Loprinzi CL, Kugler JW, Sloan JA et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J. Clin. Oncol.17(10), 3299–3306 (1999).
   PubMed Web of Science ®Google Scholar
• Willox JC, Corr J, Shaw J, Richardson M, Calman KC, Drennan M. Prednisolone as an appetite stimulant in patients with cancer. BMJ (Clin. Res. Ed.)288(6410), 27 (1984).
   PubMedGoogle Scholar
• Tataranni PA, Larson DE, Snitker S, Young JB, Flatt JP, Ravussin E. Effects of glucocorticoids on energy metabolism and food intake in humans. Am. J. Physiol.271(2 Pt 1), E317–E325 (1996).
   PubMed Web of Science ®Google Scholar
• Inui A. Cancer anorexia–cachexia syndrome: current issues in research and management. CA Cancer J. Clin.52(2), 72–91 (2002).
   PubMed Web of Science ®Google Scholar
• Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature443(7109), 289–295 (2006).
   PubMed Web of Science ®Google Scholar
• Abdel-Malek ZA. Melanocortin receptors: their functions and regulation by physiological agonists and antagonists. Cell Mol. Life Sci.58(3), 434–441 (2001).
   PubMed Web of Science ®Google Scholar
• Lu XY, Nicholson JR, Akil H, Watson SJ. Time course of short-term and long-term orexigenic effects of agouti-related protein (86–132). Neuroreport12(6), 1281–1284 (2001).
   PubMed Web of Science ®Google Scholar
• Chen HY, Trumbauer ME, Chen AS et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology145(6), 2607–2612 (2004).
   PubMed Web of Science ®Google Scholar
• Mantovani G, Macciò A, Mura L et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J. Mol. Med.78(10), 554–561 (2000).
   PubMed Web of Science ®Google Scholar
• Inui A, Asakawa A, Bowers CY et al. Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB J.18(3), 439–456 (2004).
   PubMed Web of Science ®Google Scholar
• Laviano A, Inui A, Meguid MM, Molfino A, Conte C, Rossi Fanelli F. NPY and brain monoamines in the pathogenesis of cancer anorexia. Nutrition24(9), 802–805 (2008).
   PubMed Web of Science ®Google Scholar
• Wolfgang MJ, Lane MD. The role of hypothalamic malonyl-CoA in energy homeostasis. J. Biol. Chem.281(49), 37265–37269 (2006).
   PubMed Web of Science ®Google Scholar
• von Haehling S, Doehner W, Anker SD. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc. Res.73(2), 298–309 (2007).
   PubMed Web of Science ®Google Scholar
• Sonti G, Ilyin SE, Plata-Salamán CR. Anorexia induced by cytokine interactions at pathophysiological concentrations. Am. J. Physiol.270(6 Pt 2), R1394–R1402 (1996).
   PubMed Web of Science ®Google Scholar
• Plata-Salamán CR. Central nervous system mechanisms contributing to the cachexia–anorexia syndrome. Nutrition16(10), 1009–1012 (2000).
   PubMed Web of Science ®Google Scholar
• Inui A. Cancer anorexia–cachexia syndrome: are neuropeptides the key? Cancer Res.59(18), 4493–4501 (1999).
   PubMed Web of Science ®Google Scholar
• Tecott LH. Serotonin and the orchestration of energy balance. Cell Metab.6(5), 352–361 (2007).
   PubMed Web of Science ®Google Scholar
• Heisler LK, Cowley MA, Tecott LH et al. Activation of central melanocortin pathways by fenfluramine. Science297(5581), 609–611 (2002).
   PubMed Web of Science ®Google Scholar
• Heisler LK, Jobst EE, Sutton GM et al. Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron51(2), 239–249 (2006).
   PubMed Web of Science ®Google Scholar
• Yang ZJ, Blaha V, Meguid MM, Laviano A, Oler A, Zadak Z. Interleukin-1α injection into ventromedial hypothalamic nucleus of normal rats depresses food intake and increases release of dopamine and serotonin. Pharmacol. Biochem. Behav.62(1), 61–65 (1999).
   PubMed Web of Science ®Google Scholar
• Zubareva OE, Krasnova IN, Abdurasulova IN, Bluthe RM, Dantzer R, Klimenko VM. Effects of serotonin synthesis blockade on interleukin-1β action in the brain of rats. Brain Res.915(2), 244–247 (2001).
   Google Scholar
• Langhans W, Hrupka B. Interleukins and tumor necrosis factor as inhibitors of food intake. Neuropeptides33(5), 415–424 (1999).
   PubMed Web of Science ®Google Scholar
• Barton BE. Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes. Expert Opin. Ther. Targets9(4), 737–752 (2005).
   PubMed Web of Science ®Google Scholar
• Tisdale MJ. Cachexia in cancer patients. Nat. Rev. Cancer2(11), 862–871 (2002).
   PubMed Web of Science ®Google Scholar
• Molfino A, Muscaritoli M, Cascino A et al. Free tryptophan/large neutral amino acids ratios in blood plasma do not predict cerebral spinal fluid tryptophan concentrations in interleukin-1 induced anorexia. Pharmacol. Biochem. Behav.89(1), 31–35 (2008).
   Google Scholar
• Pardridge WM, Oldendorf WH. Kinetic analysis of blood–brain barrier transport of amino acids. Biochim. Biophys. Acta401(1), 128–136 (1975).
   PubMed Web of Science ®Google Scholar
• Cangiano C, Laviano A, Meguid MM et al. Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients. J. Natl Cancer Inst.88(8), 550–552 (1996).
   PubMed Web of Science ®Google Scholar
• Hiroshige K, Sonta T, Suda T, Kanegae K, Ohtani A. Oral supplementation of branched-chain amino acid improves nutritional status in elderly patients on chronic haemodialysis. Nephrol. Dial. Transplant.16(9), 1856–1862 (2001).
   PubMed Web of Science ®Google Scholar
• Marchesini G, Bianchi G, Merli M et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology124(7), 1792–1801 (2003).
   PubMed Web of Science ®Google Scholar
• Matthews DE. Observations of branched-chain amino acid administration in humans. J. Nutr.135(6 Suppl.), S1580–S1584 (2005).
   PubMed Web of Science ®Google Scholar
• Eley HL, Russell ST, Tisdale MJ. Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem. J.407(1), 113–120 (2007).
   PubMed Web of Science ®Google Scholar
• Poon RT, Yu WC, Fan ST, Wong J. Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial. Aliment Pharmacol .Ther.19(7), 779–788 (2004).
   PubMed Web of Science ®Google Scholar
• May PE, Barber A, D’Olimpio JT, Hourihane A, Abumrad NN. Reversal of cancer-related wasting using oral supplementation with a combination of β-hydroxy-β-methylbutyrate, arginine, and glutamine. Am. J. Surg.183(4), 471–479 (2002).
   PubMed Web of Science ®Google Scholar
• Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature402(6762), 656–660 (1999).
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Nagaya N, Isobe T et al. Increased plasma ghrelin level in lung cancer cachexia. Clin. Cancer Res.9(2), 774–778 (2003).
   PubMed Web of Science ®Google Scholar
• Garcia JM, Garcia-Touza M, Hijazi RA et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J. Clin. Endocrinol. Metab.90(5), 2920–2926 (2005).
   PubMed Web of Science ®Google Scholar
• Yoshimoto A, Mori K, Sugawara A et al. Plasma ghrelin and desacyl ghrelin concentrations in renal failure. J. Am. Soc. Nephrol.13(11), 2748–2752 (2002).
   PubMedGoogle Scholar
• Nagaya N, Uematsu M, Kojima M et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation104(17), 2034–2038 (2001).
   PubMed Web of Science ®Google Scholar
• Itoh T, Nagaya N, Yoshikawa M et al. Elevated plasma ghrelin level in underweight patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.170(8), 879–882 (2004).
   PubMed Web of Science ®Google Scholar
• Hanada T, Toshinai K, Kajimura N et al. Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells. Biochem. Biophys. Res. Commun.301(2), 275–259 (2003).
   PubMed Web of Science ®Google Scholar
• DeBoer MD, Zhu XX, Levasseur P et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology148(6), 3004–3012 (2007).
   PubMed Web of Science ®Google Scholar
• Neary NM, Small CJ, Wren AM et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab.89(6), 2832–2836 (2004).
   PubMed Web of Science ®Google Scholar
• Wynne K, Giannitsopoulou K, Small CJ et al. Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial. Am. Soc. Nephrol.16(7), 2111–2118 (2005).
   PubMed Web of Science ®Google Scholar
• Nagaya N, Moriya J, Yasumura Y et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation110(24), 3674–3679 (2004).
   PubMed Web of Science ®Google Scholar
• Nagaya N, Itoh T, Murakami S et al. Treatment of cachexia with ghrelin in patients with COPD. Chest.128(3), 1187–1193 (2005).
   PubMed Web of Science ®Google Scholar
• Akamizu T, Iwakura H, Ariyasu H et al. Effects of ghrelin treatment on patients undergoing total hip replacement for osteoarthritis: different outcomes from studies in patients with cardiac and pulmonary cachexia. J. Am. Geriatr. Soc.56(12), 2363–2365 (2008).
   PubMedGoogle Scholar
• Laviano A, Meguid MM, Guijarro A et al. Antimyopathic effects of carnitine and nicotine. Curr. Opin. Clin. Nutr. Metab. Care9(4), 442–448 (2006).
   Google Scholar
• McGarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur. J. Biochem.244(1), 1–14 (1997).
   PubMedGoogle Scholar
• Vinci E, Rampello E, Zanoli L, Oreste G, Pistone G, Malaguarnera M. Serum carnitine levels in patients with tumoral cachexia. Eur. J. Intern. Med.16(6), 419–423 (2005).
   Google Scholar
• Rudman D, Sewell CW, Ansley JD. Deficiency of carnitine in cachectic cirrhotic patients. J. Clin. Invest.60(3), 716–723 (1977).
   PubMed Web of Science ®Google Scholar
• Debska-Slizień A, Kawecka A, Wojnarowski K et al. Carnitine content in different muscles of patients receiving maintenance hemodialysis. J. Ren. Nutr.17(4), 275–281 (2007).
   Google Scholar
• Gramignano G, Lusso MR, Madeddu C et al. Efficacy of L-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition22(2), 136–145 (2006).
   PubMed Web of Science ®Google Scholar
• Duranay M, Akay H, Yilmaz FM, Senes M, Tekeli N, Yücel D. Effects of L-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients. Nephrol. Dial. Transplant.21(11), 3211–3214 (2006).
   PubMed Web of Science ®Google Scholar
• Anand I, Chandrashekhan Y, De Giuli F et al. Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc. Drugs Ther.12(3), 291–299 (1998).
   PubMed Web of Science ®Google Scholar